Zaleplon improves sleep quality in maintenance hemodialysis patients.

Massimo Sabbatini, Anna Crispo, Antonio Pisani, Annalisa Ragosta, Antonio Cesaro, Francesco Mirenghi, Bruno Cianciaruso, Stefano Federico

Research output: Contribution to journalArticlepeer-review


BACKGROUND/AIM: A recent survey has shown that insomnia is still a very common problem in maintenance hemodialysis (MHD) patients. The aim of the present study was to test the effects of zaleplon (ZAL), a new nonbenzodiazepine hypnotic drug, on the sleep quality of MHD patients with insomnia. METHODS: The sleep quality was assessed by the Pittsburgh questionnaire in 10 patients (6 males/4 females) with insomnia on MHD; these patients underwent a randomized double-blind crossover study versus placebo (PLA). The main exclusion criterion was the presence of any possible cause of insomnia related to other concurrent diseases. RESULTS: Treatment with ZAL significantly improved the total score of sleep quality (p <0.03 vs. PLA). The analysis of the single components revealed that treatment with ZAL was associated with a higher subjective sleep quality (p <0.01 vs. PLA) and a reduced sleep latency (p <0.01 vs. PLA). The duration of sleep was not modified by ZAL, whereas a significant improvement was detected in habitual sleep efficacy (p <0.05 vs. PLA). No peculiar side effect was recorded on ZAL. Blood parameters did not change, nor were differences recorded in the dialysis parameters (body weight gain, blood pressure) throughout the study. CONCLUSIONS: This study suggests that ZAL has a positive effect on the sleep quality in MHD patients. The absence of side effects and its pharmacodynamic properties make ZAL a useful drug in uremic patients.

Original languageEnglish
JournalNephron - Clinical Practice
Issue number4
Publication statusPublished - 2003


Dive into the research topics of 'Zaleplon improves sleep quality in maintenance hemodialysis patients.'. Together they form a unique fingerprint.

Cite this